Journal article · 2026
Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)
The Lancet Infectious Diseases · Published 1 October 2026 · DOI 10.1016/s1473-3099(26)00469-x
In brief
“Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)” is a 2026 journal article by Marc J. M. Bonten and 24 co-authors, published in The Lancet Infectious Diseases. OpenAlex counts 1 citations as of 17 November 2026, which puts it in the top 9% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 2.89
- References
- 23
- Authors
- 25
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bonten, M. J. M., Butler, C. C., Edwards, A., Gravenstein, S., Ikeda, H., Johansen, I. S., Lambregts, M. M. C., Matsumoto, T., Patterson, D. L., Rodríguez‐Baño, J., Saade, E., Zingman, B. S., Day, T. A., Geurtsen, J., Hardt, K., McLean, C. M., Scheys, I., Shukarev, G., Guiñazú, J. R., . . . Cohen, K. A. (2026). Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace). The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00469-x
MLA 9
Bonten, Marc J. M., et al. “Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).” The Lancet Infectious Diseases, 2026. https://doi.org/10.1016/s1473-3099(26)00469-x.
Chicago
Bonten, Marc J. M., Christopher C Butler, Andrew Edwards, Stefan Gravenstein, Hiroshi Ikeda, Işık Somuncu Johansen, Merel M. C. Lambregts, et al. 2026. “Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).” The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00469-x.
Harvard
Bonten, M. J. M. et al. (2026) ‘Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)’, The Lancet Infectious Diseases. doi:10.1016/s1473-3099(26)00469-x.
IEEE
M. J. M. Bonten et al., “Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace),” The Lancet Infectious Diseases, 2026, doi: 10.1016/s1473-3099(26)00469-x.
BibTeX
@article{bonten2026efficacy,
title = {{Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)}},
author = {Bonten, Marc J. M. and Butler, Christopher C and Edwards, Andrew and Gravenstein, Stefan and Ikeda, Hiroshi and Johansen, Işık Somuncu and Lambregts, Merel M. C. and Matsumoto, Tetsuya and Patterson, David L and Rodríguez‐Baño, Jesús and Saade, Elie and Zingman, Barry S. and Day, Tracey A. and Geurtsen, Jeroen and Hardt, Karin and McLean, Chelsea M. and Scheys, Ilse and Shukarev, Georgi and Guiñazú, Javier Ruiz and Sarnecki, Michal and Spiessens, Bart and Peeters, Monika and Pau, Maria Grazia and POOLMAN, JAN T. and Cohen, Keira A.},
journal = {The Lancet Infectious Diseases},
year = {2026},
doi = {10.1016/s1473-3099(26)00469-x},
url = {https://doi.org/10.1016/s1473-3099(26)00469-x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- extraintestinal pathogenic Escherichia coli
- conjugate vaccines
- O serotypes
- older adults
- urinary tract infection
- bacteremia
- sepsis
- vaccine efficacy
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Bonten, M. J. M., Butler, C. C., Edwards, A., Gravenstein, S., Ikeda, H., Johansen, I. S., Lambregts, M. M. C., Matsumoto, T., Patterson, D. L., Rodríguez‐Baño, J., Saade, E., Zingman, B. S., Day, T. A., Geurtsen, J., Hardt, K., McLean, C. M., Scheys, I., Shukarev, G., Guiñazú, J. R., . . . Cohen, K. A. (2026). Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace). The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00469-x
How many times has this paper been cited?
1 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Marc J. M. Bonten, Christopher C Butler, Andrew Edwards, Stefan Gravenstein, Hiroshi Ikeda, Işık Somuncu Johansen, Merel M. C. Lambregts, Tetsuya Matsumoto, David L Patterson, Jesús Rodríguez‐Baño, Elie Saade, Barry S. Zingman and 13 more.
What is the DOI of this paper?
10.1016/s1473-3099(26)00469-x, permanently at https://doi.org/10.1016/s1473-3099(26)00469-x. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.